Sponsors (5)
Introduced January 14, 2026 by Pete Sessions · Last progress January 14, 2026
The bill increases access and regulatory clarity for homeopathic products—benefiting manufacturers, some clinicians, and consumers seeking those products—while substantially reducing federal oversight and legal remedies, which raises safety, consistency, and potential taxpayer‑cost risks.
People who use homeopathic products (and some practitioners) will retain broader access to those products because the bill reduces federal premarket barriers and preserves market availability.
Manufacturers and sellers (including small businesses and hospitals) gain clearer, homeopathy‑specific statutory definitions and reduced regulatory uncertainty, speeding market entry and product changes (including a predictable petition process with automatic approval timelines).
Consumers will receive more standardized on‑product information because retail labels must list supporting sources and include a standardized disclaimer, improving transparency about traditional uses and data sources.
People using homeopathic products (including Medicare beneficiaries and clinicians who advise them) face higher safety and efficacy risks because the bill reduces or removes FDA oversight, exempts some products from full identity/strength/premarket controls, and eliminates certain agency guidance.
Patients and consumers will have fewer legal remedies and less independent oversight because the bill limits FTC/state substantiation authority, preempts some claims, curtails private lawsuits, and shifts burdens toward government de novo judicial review—making it harder to challenge misleading or unsafe products.
Federal oversight reduction and statutory carve‑outs increase the risk of inconsistent standards and enforcement across states, producing variable protections for patients and health systems.
Based on analysis of 12 sections of legislative text.
Creates a separate federal regulatory pathway for homeopathic drug products, defining them, limiting FDA premarket authority, and establishing tailored GMPs and an advisory committee.
Creates a separate federal regulatory pathway for homeopathic drug products, defining them in statute and carving them out of certain existing FDA categories. It limits FDA authority for these products by prohibiting premarket approval, allowing alternative manufacturing/testing rules tailored to homeopathy, establishing a petition and review process with automatic approval deadlines, creating a new advisory committee focused on homeopathic drugs, and directing withdrawal of a recent FDA guidance for such products. The law also preserves state control over the practice of homeopathy, requires industry registration and listing, shifts certain burdens in enforcement and litigation to the federal government, and includes a severability provision so other parts remain effective if any part is invalidated.